The excitement in the field of immuno-oncology over the last several years, driven largely by the clinical success of checkpoint inhibitors, is tempered by the fact that only 10-40% of patients respond to these drugs given as monotherapy. It is widely believed that to improve efficacy and patient outcome, new approaches that combine treatments with more than one functionality are needed.
Gp96-Ig / T Cell Co-stimulator Synergy
Tumor Models: For all tumor models: 5x10 5 cells were injected into the rear flank on day 0 and mice were treated on days 4, 7 and 10 once tumors had established.
Statistical Analysis. One-way ANOVA was used for all sample group analyses. Significance is denoted by *: *p<.05, **p<.01, ***p<.001, and ****p<.0001. Sample sizes noted in experiments or from ≥3 distinct biological replicates with error as SEM.
-ComPACT amplifies antigen-specific CD4+ and CD8+ T cells at both priming and boosting, and more MPEC than OX40 agonist antibodies. -ComPACT demonstrates antigen specificity, without the off-target systemic inflammatory signature seen with OX40 agonist mAbs. -ComPACT synergizes with checkpoint inhibition (αPD1 and αPDL1) to maximize antigen-specific T cell proliferation, memory cell response, and tumor eradication. -ComPACT delivers a vaccine and co-stimulatory fusion protein in a single compound, and synergizes strongly with checkpoint inhibitors. Future combinations of the two may significantly improve patient outcomes.
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